Leucine/sildenafil/metformin

Drug Profile

Leucine/sildenafil/metformin

Alternative Names: Leu-Met-Sild; NS-0200

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NuSirt Biopharma
  • Class Biguanides; Branched-chain amino acids; Essential amino acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; SIRT1 protein stimulants; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-alcoholic fatty liver disease
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 20 Sep 2016 NuSirt Biopharma completes enrolment in its phase II trial for Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in USA
  • 10 Jun 2016 Pharmacodynamics data from preclinical studies in Non-alcohlic fatty liver disease presented at the American Diabetes Association’s 76th Scientific Sessions (ADA-2016)
  • 10 Dec 2015 Leucine/sildenafil/metformin receives Fast Track designation for Non-alcoholic fatty liver disease [PO] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top